Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:BGMS NASDAQ:CDIO NASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.72-7.1%$4.78$3.80▼$235.98$6.33M1.6835,160 shs28,175 shsBGMSCyclacel Pharmaceuticals$1.50+41.5%$1.02$0.73▼$19.87$5.85M-0.41.30 million shs104.47 million shsCDIOCardio Diagnostics$1.96-7.1%$1.85$0.97▼$7.91$6.24M2.2472,812 shs64,763 shsPRFXPainReform$1.59-11.2%$2.05$1.28▼$17.95$1.56M0.984.24 million shs323,080 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+1.20%+1.60%-5.05%-20.63%-94.31%BGMSCyclacel Pharmaceuticals0.00%+0.95%+2.91%+11.58%+105,999,900.00%CDIOCardio Diagnostics-1.86%+17.03%+15.30%-60.19%-57.72%PRFXPainReform-3.76%+30.66%-7.25%-31.68%-83.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.72-7.1%$4.78$3.80▼$235.98$6.33M1.6835,160 shs28,175 shsBGMSCyclacel Pharmaceuticals$1.50+41.5%$1.02$0.73▼$19.87$5.85M-0.41.30 million shs104.47 million shsCDIOCardio Diagnostics$1.96-7.1%$1.85$0.97▼$7.91$6.24M2.2472,812 shs64,763 shsPRFXPainReform$1.59-11.2%$2.05$1.28▼$17.95$1.56M0.984.24 million shs323,080 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+1.20%+1.60%-5.05%-20.63%-94.31%BGMSCyclacel Pharmaceuticals0.00%+0.95%+2.91%+11.58%+105,999,900.00%CDIOCardio Diagnostics-1.86%+17.03%+15.30%-60.19%-57.72%PRFXPainReform-3.76%+30.66%-7.25%-31.68%-83.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ABGMSCyclacel Pharmaceuticals 1.00SellN/AN/ACDIOCardio Diagnostics 1.00SellN/AN/APRFXPainReform 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PRFX, CDIO, APVO, and BGMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/8/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/24/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026PRFXPainReform Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/ABGMSCyclacel Pharmaceuticals$750K11.04N/AN/A$1.40 per share1.07CDIOCardio Diagnostics$10K580.16N/AN/A$3.82 per share0.51PRFXPainReform$20K69.17N/AN/A$23.07 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$25.97M-$197.60N/AN/AN/AN/A-198.50%-117.06%8/10/2026 (Estimated)BGMSCyclacel Pharmaceuticals-$3M-$4.54N/AN/AN/AN/A-51.21%-44.00%N/ACDIOCardio Diagnostics-$6.50M-$3.38N/AN/AN/A-36,950.00%-78.82%-72.87%8/13/2026 (Estimated)PRFXPainReform-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/ALatest PRFX, CDIO, APVO, and BGMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BGMSCyclacel PharmaceuticalsN/A-$0.04N/A-$0.04N/AN/A5/15/2026Q1 2026CDIOCardio DiagnosticsN/A-$0.63N/A-$0.63N/AN/A5/13/2026Q1 2026APVOAptevo Therapeutics-$6.41-$6.41N/A-$6.41N/AN/A4/6/2026Q4 2025PRFXPainReform-$612.00-$0.9850+$611.0150-$0.9850N/AN/A3/30/2026Q4 2025BGMSCyclacel PharmaceuticalsN/A-$2.21N/A-$2.21N/A$0.67 million3/26/2026Q4 2025APVOAptevo Therapeutics-$8.10$118.23+$126.33$118.23N/AN/A3/26/2026Q4 2025PRFXPainReformN/A-$1.01N/A-$1.01N/AN/A3/13/2026Q4 2025CDIOCardio DiagnosticsN/A-$0.80N/A-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ABGMSCyclacel PharmaceuticalsN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A3.363.36BGMSCyclacel PharmaceuticalsN/A7.065.87CDIOCardio DiagnosticsN/A15.7715.77PRFXPainReformN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%BGMSCyclacel Pharmaceuticals23.58%CDIOCardio Diagnostics8.06%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.08%BGMSCyclacel Pharmaceuticals23.75%CDIOCardio Diagnostics13.30%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics501.25 million1.25 millionNot OptionableBGMSCyclacel Pharmaceuticals145.52 million4.21 millionN/ACDIOCardio Diagnostics12.96 million2.57 millionNot OptionablePRFXPainReform4870,000570,000Not OptionablePRFX, CDIO, APVO, and BGMS HeadlinesRecent News About These CompaniesPRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy MarketsMay 28, 2026 | globenewswire.comPRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical StudyMay 26, 2026 | globenewswire.comPRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical TrialApril 28, 2026 | globenewswire.comPRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsMarch 27, 2026 | globenewswire.comPRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial EngagementsMarch 17, 2026 | globenewswire.comPRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | markets.businessinsider.comPRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | globenewswire.comPRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial BaseFebruary 11, 2026 | globenewswire.comPRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJanuary 20, 2026 | globenewswire.comPainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy PushJanuary 16, 2026 | benzinga.comPainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy PushJanuary 16, 2026 | benzinga.comPainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy PlatformsJanuary 15, 2026 | finance.yahoo.comPainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven EnergyJanuary 15, 2026 | tipranks.comPainReform Ltd. Changes Name to PRF Technologies Ltd.January 15, 2026 | globenewswire.comPainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesJanuary 12, 2026 | markets.businessinsider.comPainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesJanuary 12, 2026 | globenewswire.comPainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial ComparisonJanuary 10, 2026 | defenseworld.netDPainReform Files Pro Forma Financials Following Majority Acquisition of LayerBioJanuary 7, 2026 | tipranks.comPainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJanuary 5, 2026 | markets.businessinsider.comPainReform Ltd. Launches Smart TDD: Advanced Solar Technical Due Diligence Service to Enhance Asset Performance and Risk AssessmentJanuary 5, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, CDIO, APVO, and BGMS Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.72 -0.36 (-7.09%) Closing price 04:00 PM EasternExtended Trading$4.76 +0.04 (+0.85%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cyclacel Pharmaceuticals NASDAQ:BGMS$1.50 +0.44 (+41.51%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.26 (+17.27%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.Cardio Diagnostics NASDAQ:CDIO$1.96 -0.15 (-7.11%) Closing price 04:00 PM EasternExtended Trading$2.05 +0.09 (+4.39%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.PainReform NASDAQ:PRFX$1.59 -0.20 (-11.17%) Closing price 04:00 PM EasternExtended Trading$1.57 -0.02 (-1.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
